IGF-1, Sarcopenia and Mortality: a Cohort Study in Patient With Cognitive Impairment

Insulin-like growth factor 1 (IGF)-1 is an important neuromyotrophic hormone. Disregulation of this hormone has been reported to influence the genesis of cognitive impairment and dementia in the elderly patients. We analyzed the possible link between IGF-1 and risk of Sarcopenia and Mortality in a cohort of elder patients with cognitive impairment.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Cognitive Impairment Atrophy Cognition Disorders Cognitive Dysfunction Insulin-like Growth Factor 1 Mental Disorders Muscular Atrophy Nervous System Diseases Neurocognitive Disorders Neurologic Manifestations Neuromuscular Manifestations Pathological Conditions, Anatomical Pathological Conditions, Signs and Symptoms Sarcopenia Signs and Symptoms

Age range

65 year–90 year

Sex eligibility

All sexes

Study type

Observational

Primary location

IRCCS Galeazzi, Milan, Italy

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Diagnosis of cognitive impairment (MMSE < 24)
Age > 65 ys

Exclusion criteria

Diagnosis of pancreatic disorders
Diagnosis of acromegaly
Diagnosis of GH-related disorders
Recent bone fractures or immobility before the enrollment (3 months)
Cancer

Treatment and study plan

IGF-1 serum value

Procedure

Evaluation of IGF-1 serum value at baseline, 24 and 48 months

Primary outcomes

IGF-1 reduction in patients with sarcopenia

Time frame: baseline, 24 months, 48 months

IGF-1 reduction could be linked to sarcopenia in patients with cognitive impairment

Secondary outcomes

IGF-1 reduction and mortality in patients with cognitive impairment

Time frame: baseline, 24 months, 48 months

IGF-1 could be an independent risk factor for mortality in patients with cognitive impairment

Sponsors and collaborators

Lead sponsor

University of Roma La Sapienza

Other

Registry information

Official study title

Insulin Like Growth Factor 1 and Risks of Sarcopenia and Mortality in Patients With Cognitive Impairment

Acronym: ISAAC

Important dates

Study start: 2008
Primary completion: 2013
Study completion: 2013
First posted: May 15, 2014
Registry last updated: May 15, 2014

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed